Vaxcyte (PCVX) Other Working Capital Changes (2024 - 2026)

Vaxcyte (PCVX) has 3 years of Other Working Capital Changes data on file, last reported at -$1.3 million in Q1 2026.

• On a quarterly basis, Other Working Capital Changes fell 108.03% year-over-year to -$1.3 million in Q1 2026; TTM through Mar 2026 was $29.1 million, a 51.27% decrease from a year earlier, with the FY2025 full-year figure at $46.4 million, up 10.71% from the prior year.
• Other Working Capital Changes for Q1 2026 stood at -$1.3 million, down from $33.1 million in the prior quarter.
• Over the last five years, Other Working Capital Changes for PCVX reached as high as $24.0 million in Q4 2024 and fell as low as -$16.5 million in Q4 2023.
• Historically, Other Working Capital Changes has averaged $2.5 million across 5 years, with a median of $1.6 million in 2022.
• On a YoY basis, Other Working Capital Changes climbed as much as 986.86% in 2025 and fell as far as 158.92% in 2025.
• Year by year, Other Working Capital Changes stood at $43.2 million in 2024, then retreated by 23.21% to $33.1 million in 2025, then tumbled by 103.88% to -$1.3 million in 2026.
• Per Business Quant data, the three most recent Other Working Capital Changes figures were -$1.3 million in Q1 2026, $33.1 million in Q4 2025, and -$1.4 million in Q3 2025.